This activity is no longer available for credit, however its content is still relevant for your educational needs.
Statement of Need
The purpose of this activity is to enhance knowledge concerning the treatment of patients with multiple myeloma (MM).

Target Audience
This activity was developed for physicians, nurses, and pharmacists.

Learning Objectives
At the completion of this activity participants should be able to:

• Identify novel induction regimens used to treat multiple myeloma (MM)
• Explain therapeutic options for patients with MM who are not candidates for stem cell transplantation
• Review the role of novel therapies in the treatment of relapsed/refractory MM
• Interpret the implications of emerging clinical trial data and apply relevant information to current clinical practice

Disclosure Statement
Before the activity, all faculty and anyone who is in a position to have control over the content of this activity will disclose the existence of any financial interest and/or relationship(s) theymight havewith themanufacturer(s) of any commercial products(s) to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers’ bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:



Faculty Disclosures
Kenneth Anderson, MD is on the advisory board for Celgene, Gentium, Millennium, and Novartis, has received grant/research support from Celgene, Millennium, and Novartis, has received honoraria from Celgene, Millennium, and Novartis, and is on the speaker's bureau for Celgene and Millennium.

Jean-Luc Harousseau, MD, is on the advisory boards and speaker's bureau for Celgene and Janssen-Cilag.

Michele Cavo, MD, has no relationships to disclose.

Bart Barlogie, MD, PhD has received research support from Celgene, Millennium, and Novartis and honoraria from Celgene and Millennium. He also serves as a consultant for Celegene and Genzyme and is on the the speaker's bureau for Celgene, Genzyme, and Millennium.


*Content will include non-FDA-approved uses.

Disclaimer
The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition.